TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Lipodystrophy (Lipoatrophy). According to GlobalData, Phase I drugs for Lipodystrophy (Lipoatrophy) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TLC-6740 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TLC-6740 overview

TLC-6740 is under development for the treatment of lipodystrophy, insulin resistance, obesity, diabetes and nonalcoholic steatohepatitis (NASH). The drug candidate is a liver-targeted, mitochondrial protonophore (CRMP). It is administered through oral route.

OrsoBio overview

OrsoBio formerly Liver, is a clinical-stage biopharmaceutical company that engaged in developing therapies for the treatment of severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. The company is headquartered in Palo Alto, California, the US.

For a complete picture of TLC-6740’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.